Letters

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
• 
Pitfalls in Measuring Cytokines
To the Editor: Casey and colleagues (1) note the potential importance of measuring cytokine levels in patients with systemic sepsis, whereas Dinarello and Cannon (2) detail many of the pitfalls associated with assaying cytokine levels. We report some other difficulties inherent in measuring "immunoreactive" tumor necrosis factor (TNF)-a by enzyme-linked immunosorbent assay (ELISA). As noted by Casey and colleagues (1), the assessment of TNF-a immunoreactivity reflects the level of the biologically active and inactive forms of TNF-a. However, the level of im- Figure 1 . In the ELISA kit used by Casey and colleagues (1) (T Cell Science, Cambridge, Massachusetts), the level of TNF-a immunoreactivity was masked by 75% and 60%, respectively, in the presence of type 1 TNF-binding proteins and type 2 TNFbinding proteins. In contrast, the level of immunoreactive TNF-a measured by an ELISA kit from a second vendor (Genzyme Corp., Cambridge, Massachusetts) was not affected by the type 1 proteins, whereas TNF-a immunoreactivity was masked by 80% in the presence of the type 2 proteins. Finally, levels of immunoreactive TNF-a measured by an ELISA kit from a third vendor (R&D Systems, Minneapolis, Minnesota) were not masked by either type of protein.
Although Casey and colleagues (1) have made an important contribution regarding the clinical significance of cytokine profiles in septic shock, it is critically important for the scientific community to standardize the methods used to measure cytokine levels in future trials. In response: Numerous assays are available to investigators for measuring cytokines, and a study by Parson and colleagues (1) shows that different assays yield different results. Which is correct? Why are there differences? The data from Dr. Mann and colleagues show that the presence of circulating soluble receptors to TNF may interfere with TNF immunoassays, depending on the assay kit. In the data presented, 500 ng/mL of the circulating soluble receptors resulted in the loss of detection of TNF by using the assay kit we used. However, the concentration of these receptors in their study was approximately 50 times higher than that in septic patients. Thus, the importance of their results is unclear.
Nevertheless, Dr. Mann and colleagues do raise important issues. Which is more critical to measure: total circulating TNF, TNF bound to its soluble receptor, or free TNF? Because TNF becomes inactive when bound to its receptor, and the infusion of the receptors improves outcome in septic animals, the quantitation of TNF that is bound to its soluble receptors may not be as important as free TNF. The free bioactive TNF that binds to TNF receptors on cells to induce cell activation may then contribute to the morbidity and mortality associated with sepsis.
In the study by Mann and colleagues, the assay kit from T Cell Science [vendor 1] did not detect TNF in the presence of its soluble receptor, whereas the kit from Genzyme Corp. [vendor 3] detected TNF even in the presence of high concentrations of the receptors. If you are using an in vitro cell culture system and you want to know the total amount of TNF produced by the cell, the assay kit from Genzyme Corp. might be better; if you are interested in the amount of free TNF, perhaps the kit from T Cell Science would be better. Even bioassays will not circumvent the limitations of immunoassays. Synergistic interactions exist between low levels of cytokines, resulting in an overestimation of the amount of cytokine present, and, in the case of interleukin-1, the endogenously produced interleukin-1-receptor antagonist interferes with the interleukin-1 bioassay. Interleukin-6 will still trigger a biological response, even if bound to its soluble receptor. Assays for cytokines are still evolving, and investigators should recognize that different assays may yield different results. 
Larry
Controversy over Sclerotherapy for Malignant Pleural Effusions
To the Editor: The review of chemical pleurodesis by WalkerRenard and colleagues (1) was informative, but their conclusion on the efficacy and cost of these agents must address efficacy, the patient-practitioner relationship, and cost.
Most of my statements here are directed toward the comparison of doxycycline with bleomycin, for which the literature for minocycline is preliminary. In their review, Walker-Renard and associates conclude that the first-dose efficacies, defined as complete responses, of doxycycline and bleomycin are 10% and 54%, respectively. For doxycycline, cumulative second-dose effectiveness is 20% and third-dose efficacy is 43%. It was not until the fourth dose of doxycycline that the efficacy resembled that of the first dose of bleomycin (53% to 54%) (1). Robinson and colleagues (2) published the best results to date of using doxycycline for sclerotherapy. Of 21 patients initially treated, only 17 were evaluated. Two died (with chest tubes in place) because of their rapidly progressing diseases, and 2 died within the 30-day follow-up period. Patients were given 500 mg of doxycycline in sterile water with lidocaine and were monitored for 24 hours. Thirteen (62%) patients responded to one instillation, 6 to two doses (29%), and the other 2 to three instillations (10%). The authors report an overall success rate of 88% (15 of 17 patients) at 1 month. It is important to note that three patients were treated with urokinase before receiving sclerotherapy (2) . These results need to be confirmed to exclude the possibility of error because of sample size.
Several patient-care issues must also be addressed. Doxycycline requires multiple instillations (an average of four in the review by Walker-Renard and associates), usually over several days (1) . Bleomycin, requiring only one dose, allows the chest tube to be removed more rapidly, thus reducing patient discomfort and the time-related risk for infection. One could speculate that patients treated with bleomycin may be less prone to experience the emotional stress and depression or anxiety that are associated with multiple instillations (1).
Walker-Renard and associates state that the average wholesale prices are $403 for doxycycline at 2 g (500 mg for four doses) and $1104 for bleomycin at 70 mg. These are the only costs that would have to be considered if all four instillations could be done on the same day. However, in the studies cited in the review article, only one sclerosis was done per day. This requires the addition of the cost per day of hospital stay to be added to the equation for the true cost of therapy. The average cost for a day in the hospital is $752 (3) . Adding 2 to 3 extra days of hospitalization to the cost of treatment with doxycycline increases the cost of therapy by $1500 to $2250. This suggests that bleomycin is a more cost-effective therapy. To the Editor: The article by Walker-Renard and colleagues, although well written and researched, reaches unwarranted and misleading conclusions. The authors have, in effect, done a metaanalysis without following the rigorous procedures required for such an analysis (1).
Dennis K Fuller, PharmD
The conclusion that "doxycycline and minocycline, with success rates of 72% and 86%, respectively, appear to be effective tetracycline-replacement agents in the few patients studied," is particularly misleading. The minocycline data are based on a sample of seven patients (2) . The total doxycycline experience of 60 patients from three trials showed only a 10% response to the first dose of doxycycline as noted in Table 1 of their manuscript. This is critical when one of the reasons for dismissing bleomycin as the current agent of choice is its cost. Bleomycin was found to be superior to tetracycline in the only randomized trial for treatment of malignant pleural effusions (3), and its cost, as noted in their Table 3 , is approximately $1000, although the recommended dose is 60 units rather than 1 unit/kg, which would give a dose of 70 units for the "average" 70-kg patient (3) . If 90% of patients require several days in the hospital to obtain a response (with doxycycline doses given at least 1 day apart to assess response), the cost will rapidly exceed that of one dose of bleomycin. In addition, the use of soft catheters in the ambulatory setting instead of hospitalization for chest tube placement is not feasible if multiple doses are required (4) .
Talc is the agent with the highest response rate to date, but until recently it was given in the operating room through insufflation. The costs of anesthesia, surgery, and several days of hospitalization far exceed the cost of one dose of bleomycin, even in those patients who can tolerate an operation (5). The technique of using a talc slurry through a chest tube also shows promise but has suffered from the absence of available material in a sterile form and has not been tested in a randomized trial. Critical to any discussion of health care costs is inclusion of the entire episode of care, not just the cost of one component.
A National Cancer Institute intergroup trial will soon compare intrapleural talc (5 g through slurry), bleomycin (60 units), and doxycycline (500 mg). Until the completion of the trial, we will have no accurate data on the relative merits of talc slurry and doxycycline. This trial will address costs by recording the number of hospital days plus the need for any re-treatment at the time of recurrence. In the interim, we recommend the use of bleomycin, which has been recently approved by the Food and Drug Administration Advisory Committee for the management of malignant pleural effusions.
To the
Inexplicably, one of the most important agents, quinacrine, was omitted. Far more commonly used than most of the chemicals discussed, quinacrine is an extremely effective agent. For example, within the last year it was shown to be superior to bleomycin in a randomized study (2) . Two other relevant studies are cited here that allow the reader to access the 20 to 30 articles on the subject, detailing experiences with more than 100 patients (3, 4 To the Editor: Walker-Renard and colleagues (1) did not consider the potential use of autologous blood for pleurodesis. It has been used for various pleural diseases, including recurrent and chronic spontaneous pneumothorax (2), massive hydrothorax (3), and persistent pulmonary air leak (4).
Sedlarik and colleagues (5) described the use of electrically activated autologous blood for pleurodesis in a 48-year-old patient with malignant pleural effusions. The patient required pleurodesis of 60 mL, 50 mL, and 50 mL of electrically activated autologous blood at 10-day intervals with complete response during the 11 months the patient survived. This technique does not require a chest drain and is not associated with significant procedural or postprocedural pain. This cheap and effective method has no theoretical possibility for transmission of the human immunodeficiency virus.
Mumtaz A. Siddiqui, MD
The Graduate Hospital Philadelphia, PA 19146 In response: The 1993 retrospective review in 21 patients mentioned by Fuller (1) that showed a complete response of 88% after 1 month with the use of 500 mg of intrapleural doxycycline was not available when our review was done. We agree that the issues raised by Drs. Fuller and Ruckdeschel concerning firstdose efficacy, length of hospital stay, and total costs require further study; however, we disagree that sufficient comparative data exist to state that bleomycin is more efficacious and costeffective than doxycycline, particularly because higher doxycyline doses may have produced different results (2, 3) . It is hoped that more definitive answers will be provided by the results of the comparative National Cancer Institute Intergroup Trial. Our review was not a meta-analysis, nor was it designed to be one. A meta-analysis or formal research overview sets criteria for acceptance of study trials and attempts to integrate statistical end points; such reviews are "systematic reviews of specific clinical questions that use statistical methods to combine the results of previous research" (4). Our review consisted of data extracted from all identified trials and combined into summary totals, a process that, unlike meta-analysis, is easily repeatable by others. Dr. Ruckdeschel's point concerning the superiority of bleomycin over tetracycline in the only randomized trial is moot because of the unavailability of tetracycline. A recent report of death associated with intrapleural bleomycin should be noted (5) .
We thank Drs. Wallace and Siddiqui for acquainting us with the recent literature on the use of intrapleural quinacrine and autologous blood, respectively. Because a United States Pharmacopeia formulation is unavailable, clinicians may have a concern regarding the source, purity, and sterility of acquired quinacrine in the United States. 
Leeching, Hirudin, and Coagulation Tests
To the Editor: In his review of the medicinal leech, Adams (1) referred to leeching in the prevention of postoperative thromboses. Lillienthal (referenced by Adams) wrote that "In early thrombophlebitis ... application of leeches ... will usually ... be followed by amazingly rapid and complete recovery" (2) . Despite the continued use of leeches in reconstructive surgery, no published data describe the effect of leeching on modern tests of coagulation. We conducted two such experiments. Two Hirudo medicinalis were attached to the dorsal left hand of one investigator, and ipsilateral and contralateral values of activated clotting time, thrombin time, activated partial thromboplastin time, and prothrombin time were measured from the cephalic or median cubital vein. No effect on clotting times was noted during 2.5 hours. The second experiment, in which nine leeches were attached, was done 3 weeks later (Figure 1 ). All leeches fed until sated and spontaneously released after 40 to 90 minutes. The triradiate bite marks bled for 5 to 12 hours after detachment and were compressed. No changes in ipsilateral activated partial thromboplastin time or prothrombin time were noted 15, 60, 120, or 180 minutes after the first attachment (Table 1) ; the last sample was obtained 90 minutes after the last leech detached.
Natural and recombinant hirudin are nearly completely absorbed after subcutaneous injection, with peak plasma levels occurring at 1 to 2 hours (3), making it unlikely that a delayed systemic antithrombin effect was missed in our experiments. It seemed reasonable to conclude that the "dose" was insufficient, and we endeavored to generate an estimate of a "therapeutic dose" of leeches in humans.
In GUSTO II, a randomized trial of heparin compared with intravenous hirudin in the treatment of acute myocardial infarction or unstable angina, a hirudin bolus of 0.6 mg/kg plus an infusion of 0.2 mg/kg per hour was used, producing an approximate two-to threefold elevation of the activated partial thromboplastin time (GUSTO II Protocol. Unpublished data). Leeches weigh approximately 2 g, and one can extract approximately 80 to 140 000 thrombin inhibitory units of crude hirudin from 1 kg of leeches (4) . Recombinant hirudin contains 16 000 thrombin inhibitory units/mg of protein (5) . Thus, the infusion dose in GUSTO II for an 80-kg person is 256 000 thrombin inhibitory units/h, the equivalent of the total extractable hirudin from 1280 H. medicinalis.
In addition to hirudin, leech saliva contains several active substances, including inhibitors of platelet aggregation (6) . Although these substances may enhance the antithrombotic effect of leech hirudin, direct observations and pharmacokinetics suggest that physicians who have previously practiced leeching were not likely to have produced a regional or systemic anticoagulant effect. For modern practitioners of leeching, systemic bleeding is unlikely to complicate the therapy.
Sucralfate and the Absorption of L-Thyroxine
To the Editor: Although an in vitro study showed binding of L-thyroxine by sucralfate (1), a later study showed that sucralfate did not interfere with in vivo absorption of replacement L-thyroxine in patients with hypothyroidism (2) . After encountering such a patient receiving replacement L-thyroxine who experienced a decrease in serum thyroxine (T 4 ) index and a dramatic increase in serum thyrotropin after starting treatment with sucralfate, we studied the effect of sucralfate on L-thyroxine absorption.
After obtaining informed consent and baseline tests, nine patients with primary hypothyroidism were randomly assigned to treatment with sucralfate, 1 g 4 times daily or placebo, one capsule 4 times daily. The mean age was 37 years (range, 20 to 57 years), and the mean daily dose of L-thyroxine was 133 /ig (range, 75 to 200 jug). Thyroid tests were obtained after 4 weeks of treatment. Therapy was discontinued for 2 weeks, and the patients then crossed over to the other study medication for 4 weeks. Both patients and investigators were masked to treatment and test results. All patients remained on their starting dose of L-thyroxine throughout the study. The results are shown in Table  1 .
When compared with placebo, treatment with sucralfate produced a modest decrease in the serum T 4 index (P = 0.038) and an increase in serum thyrotropin (P = 0.097) that was not statistically different. Only one patient treated with sucralfate developed an elevated serum thyrotropin level, and she also had an elevated thyrotropin value while receiving placebo, suggesting that she was not taking her medications reliably. Thus, our data suggest that sucralfate does not have a major effect on L-thyroxine absorption. However, because of the potential for a decrease in the serum T 4 index, thyroid function tests should be monitored during concomitant therapy with L-thyroxine and sucralfate. 
Other Approaches to Primary Care Training
To the Editor: The articles in the 1 December 1993 Annals (1-3) were timely and of great interest to those of us beginning our careers in internal medicine. Most internists would agree with Drs. Petersdorf and Goitein (2) that "the general internist continues to be the best primary care physician for adults." They also state that recent gains in family medicine residencies reflect enrollment students' beliefs that they provide more breadth than do the current internal medicine residency.
What all three articles failed to address, however, is that we in internal medicine have an excellent answer to this contention. Since the 1960s, programs in combined internal medicine and pediatrics have produced "general and family" practitioners who provide both breadth and depth in internal medicine and pediatrics! These persons are fully trained internists and pediatricians and thus have the ability to provide comprehensive outpatient as well as inpatient care to patients of all ages. They receive pediatrics training in addition to the same training as categorical internal medicine residents receive. These programs provide trainees with the ability to treat complex, multisystem disease, not usually provided in traditional family practice residencies. The trainee has the added advantage of being able to treat the "whole family."
As a graduate of such a program, I believe that it is an excellent alternative to the standard family practice, internal medicine, and pediatrics residencies. Most of our graduates go on to provide primary care to smaller communities where they are often the only internist or pediatrician. Some graduates choose to pursue subspecialty training in either internal medicine, pediatrics, or, occasionally, both. This option should remain available. Persons in policymaking positions should carefully examine the program as an alternative to our present training methods.
J. Thomas Cross, Jr., MD, MPH University of Arkansas for Medical Sciences Little Rock, AR 72205
To the Editor: As practicing academic general internists, we believe that the perception of "The Future of Internal Medicine," (1) although provocative, predominantly portrays a doom and gloom situation. The authors advocate a strong but separate identity for general internal medicine to increase recruitment by enhancing its status-a nonintegrated approach. We propose a more integrated approach by shedding the boundaries between general internal medicine, family medicine, and pediatrics.
Why not establish student and residency programs with crosscultural training? Residents could choose to complete 2 years of internal medicine with either 2 years of family medicine, 2 years of pediatrics, or a combination of both. At the end, they would be eligible for two separate boards. This would prepare residents to cope with many different medical problems in any setting. With 4-year training, physicians would be less inclined to do further subspecialty training, thus limiting subspecialization to physicians genuinely interested in a specific area. Ability to handle complex problems would reduce referrals. Such a program would launch us into the 21st century of medicine with greater flexibility and a clearer definition of the primary care physician's role.
In response: I agree with Dr. Cross's comment. My colleagues from Ohio propose what is in essence a generic training program in primary care. This idea is not new and has been discussed many times among the leaders of the involved disciplines. In fact, I spent many meetings engaged in this academic form of "indoor sport." Although intellectually appealing, a unified primary care training experience seems difficult in view of the biopolitical issues involved. Each of the specialties has a different reason for maintaining its turf. Rehashing the logic of their reasoning would serve no useful purpose here. Suffice it to say that although many good reasons exist for studying and implementing the plan proposed by the writers of this letter, I am afraid that most physicians in internal medicine, family medicine, and pediatrics are not ready to accept it.
Robert G. Petersdorf, MD Association of American Medical Colleges Washington, DC 20037-1126
Don't Share Razors or Toothbrushes
To the Editor: Dr. Shapiro's review (1) of the transmission of hepatitis viruses was excellent. He noted that those with hepatitis B virus or C virus infection should not share razor blades or toothbrushes. The Centers for Disease Control and Prevention made a similar recommendation regarding the human immunodeficiency virus. Razors and toothbrushes are frequently contaminated with blood and come into contact with nonintact skin or mucous membranes. In a health care setting, they would be considered semi-critical instruments that require high-level disinfection between patients (2).
Those who work in hospitals, where even the bedpans are disposable, may find it obvious that razors and toothbrushes should not be shared. It is not obvious to everyone. A leading consumer magazine recently advocated sharing razors within households (3). The author is aware of shared razors in a mental institution, a nursing home, a barber shop, and prisons.
Household transmission of hepatitis B virus occurs with some frequency, but the mechanisms are poorly understood (1, 4) . Among New Zealand adolescents, household sharing of toothbrushes was the strongest risk factor for hepatitis B virus seropositivity (odds ratio, 5.18; CI, 1.42 to 18.92) (4) . Household transmission of HIV is known to be rare, but a shared razor blade was suspected in one case (5) . The major routes of transmission for blood-borne pathogens are sexual, percutaneous, and mother-to-infant. However, a simple recommendation can be made: Razors and toothbrushes should not be shared in households or institutions.
for transmission of hepatitis viruses and other blood-borne viruses (1) .
Craig N. Shapiro, MD Centers for Disease Control and Prevention Atlanta, GA 30333
